Department of Medicine, University of Massachusetts Medical School, Worcester, MA, US.
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, US.
Hepatology. 2019 May;69(5):2271-2283. doi: 10.1002/hep.30369. Epub 2019 Jan 15.
A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre-specified treatment endpoints. A table summary of these goals and aims is provided in the context of epidemiology, current management strategies, next steps for future trials and translational science.
2017 年 9 月 30 日和 10 月 1 日，欧洲肝脏研究学会（EASL）和美国肝脏研究学会（AASLD）在伦敦联合召开了会议。会议的目的是确定广泛共识和分歧领域，制定共识，并确定未来的方向，以最终减轻酒精性肝病（以前称为酒精性肝病）的负担、发病率和死亡率。会议的具体目标是确定未来研究的未满足需求和领域，以减少酒精的摄入，开发疾病诊断和预后的标志物，并创建一个框架来测试具有预先规定治疗终点的新型药理学药物。在流行病学、当前管理策略、未来试验和转化科学的下一步中提供了这些目标和目的的表格摘要。
